Global Biochip Markets: Microarrays and Lab-on-a-Chip

• Publication date: August 2011

REPORT HIGHLIGHTS * The global value of the overall biochips market, by end use was $3.5 billion in the year 2010. The size of the biochips market will increase from $3.9 billion in 2011 to nearly $9.6 billion by 2016, a compound annual growth rate (CAGR) of 19.5%. * Tools markets for biochips will experience slowing growth due to maturation of some market segments-including gene expression analysis and single nucleotide...

REPORT HIGHLIGHTS

* The global value of the overall biochips market, by end use was $3.5 billion in the year 2010. The size of the biochips market will increase from $3.9 billion in 2011 to nearly $9.6 billion by 2016, a compound annual growth rate (CAGR) of 19.5%.
* Tools markets for biochips will experience slowing growth due to maturation of some market segments-including gene expression analysis and single nucleotide polymorphism (SNP) genotyping. This market will grow at a CAGR of 8.4% from 2011 to 2016 and will reach to $2.7 billion.
* The diagnostics market segment is set for high growth. This market was around $1.05 billion in 2010 and is expected to reach $2 billion by 2011. The diagnostics market is forecasted to grow at a CAGR of 28.2% and to reach $4.1 billion by 2016.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC’s goal for this study was to determine the status of current and emerging biochip technologies and products and assess their worldwide growth potential over a 5-year period from 2011 to 2016. We were particularly interested in characterizing the biochip markets by type (DNA microarray, protein microarray, emerging microarray, lab-on-a-chip); by function (gene expression, genotyping, micro-RNA, epigenetic, sequence capture); and by end user research and development ((R&D) tools, drug discovery, and development, diagnostics, sequencing, applied).

A particular focus of this study is the market for biochip-based diagnostics products, which highlights a major future market segment for biochips.

Our key objective was to present a comprehensive discussion of the main commercial biochip technologies and the current and future commercial potential for each of the key market segments.

REASONS FOR DOING THE STUDY

BCC previously examined the biochips industry in 2009. Since 2009, numerous industry alliances and acquisitions have occurred, which alters the competitive dynamics. In addition, more biochips-based diagnostics have been launched, as well as next-generation sequencing systems. At the same time, several market segments have been affected by a slowdown in the genome-wide association market. Given the changing industry dynamics and market shifts occurring in this industry, it is timely to re-examine the biochips business.

It is important to keep abreast of the main biochips platforms: DNA microarrays, protein microarrays, and lab-on-a-chip. DNA microarrays are an established technology generating substantial revenue derived from gene expression, genotyping, epigenetic, and micro-RNA applications. Protein microarrays are gaining prominence in the marketplace, while future, emerging array technologies, including tissue/cell and glycomics arrays are increasing in importance. Lab-on-chip devices are also making rapid progress in important pharmaceutical and diagnostics market segments.

This report is intended to guide companies in these industries about the important trends in biochips as well as provide detailed information about the individual market segments and industry dynamics.

INTENDED AUDIENCE

BCC has compiled a study of critical biochip technologies that are used in the five major end-user segments: research tools; drug discovery and development; diagnostics; sequencing; and applied markets. The report discusses the biochip platforms, market growth driving forces, product types, key market applications, companies and alliances, industry dynamics, patents, future market potential, and product sales forecasts for the period 2011 through 2016.

This study will be of particular interest to the companies in the following industries: diagnostics, pharmaceuticals, biotechnology, nanotechnology, life sciences tools, biodefense, medical devices, polymers, glass, bioinformatics, and genetic services. It will also be of interest to companies involved in drug and/or biomarker discovery programs; manufacturers of microarrays and lab-on-a-chip devices, antibodies, restriction enzymes, or primers; bioinformatics developers; and cancer researchers and clinicians.

SCOPE AND FORMAT OF REPORT

The study scope includes the major biochip platforms that are likely to become commercialized within the next 5 years. Each technology is analyzed to determine its market status, impact on future market segments, and forecasted growth from 2011 through 2016. Technology status and market driving forces are discussed. Factors that influence the market are discussed, including growth driving forces; industry alliances and acquisitions; applications in diagnostics and drug discovery; customer needs; and competitive trends.

BCC also examines specific market segments, including digital polymerase chain reaction (PCR); China biochips; and peptide microarrays. We also examine patent strategies within the industry. 140 companies are profiled in the report.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC examines each of the key end-user market segments that will be commercially important during the next five years: research tools; drug discovery and development; diagnostics; next-generation DNA sequencing; and applied markets (biodefense, food safety, ag-bio).

Based on this analysis, we evaluate the potential applications of biochips in each of the major market segments, and forecast sales revenues for 2011 through 2016.

For research tools and drug discovery and development, the study presents a forecast from 2011 through 2016 for each of the important products and technologies. For DNA microarrays, the study forecasts market size by application and analysis type. For diagnostics, the report forecasts from 2011 through 2016 the demand for biochips by chip type and by indication, as well as cancer biochips by type and application. This study forecasts from 2011 through 2016 the market for lab-on-a-chip (LOAC) devices by end-use market and by application. The geographical markets are forecast for each biochip type.

INFORMATION SOURCES

BCC surveyed life science companies and research institutions to obtain data for this study. Included were research tools firms, diagnostics firms, drug firms, microarray and lab-on-a-chip companies, and leading microarray research institutions. We also spoke with users of in-vitro personalized medicine devices. In addition, we compiled data from secondary sources, including industry, trade, and government.

Global Genomics Industry

CHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
INTENDED AUDIENCE 2
SCOPE AND FORMAT OF REPORT 2
METHODOLOGY 2
INFORMATION SOURCES 3
ANALYST’S CREDENTIALS 3
RELATED BCC REPORTS 4
BCC ONLINE SERVICES 4
DISCLAIMER 4
CHAPTER TWO: SUMMARY 5
SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY
END USE, THROUGH 2016 ($ MILLIONS) 5
SUMMARY FIGURE GLOBAL VALUE OF BIOCHIP PRODUCTS BY
END USE, 2010-2016 ($ MILLIONS) 6
SUMMARY (CONTINUED) 7
CHAPTER THREE: OVERVIEW 8
INTRODUCTION 8
TABLE 1 BIOLOGY DOWNSIZING REVOLUTION 9
BIOCHIP TYPES 9
TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES 10
TABLE 3 BIOCHIP NOMENCLATURE 11
SCOPE OF REPORT 12
TABLE 4 SCOPE OF REPORT 12
MARKET POTENTIAL OF BIOCHIPS 12
TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY
TECHNOLOGY, THROUGH 2016 ($ MILLIONS) 13
TABLE 6 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY
FUNCTION, THROUGH 2016 ($ MILLIONS) 14
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS 15
TABLE 7 FORCES DRIVING BIOCHIPS GROWTH 15
GROWTH IN LIFE SCIENCE R&D FUNDING 16
TABLE 8 2009-2010 STIMULUS FUNDING ALLOCATED TO US
SCIENCE SPENDING, ($ MILLIONS) 16
LARGE-SCALE GENOMIC, PROTEOMIC AND BIOCHIP
INITIATIVES 17
DEVELOPMENT OF TARGETED, PERSONALIZED
MEDICINES 17
COST CONSCIOUS HEALTHCARE SYSTEM 18
RAPIDLY AGING POPULATION IN DEVELOPED REGIONS 18
NEED FOR MORE INNOVATIVE DIAGNOSTIC TESTING
FORMATS 18
ONGOING DISCOVERIES IN GENOMICS AND
PROTEOMICS 19
DISCOVERY OF GENE AND SNP DISEASE ASSOCIATIONS 19
THE BIOCHIP INDUSTRY 19
TABLE 9 COMPARISON OF BIOCHIPS INDUSTRIES 20
CHAPTER FOUR: MICROARRAY TECHNOLOGIES 21
INTRODUCTION 21
THE NANOSCALE WORLD 21
TABLE 10 THE NANOSCALE WORLD 21
TABLE 11 MICROARRAY TYPES 22
TABLE 12 COMPARISON OF DNA AND PROTEIN MICROARRAY
TECHNOLOGIES 22
TABLE 12 (CONTINUED) 23
DNA MICROARRAY TECHNOLOGIES 24
INTRODUCTION 24
FIGURE 1 MICROARRAY FEATURE DENSITY 24
FIGURE 2 MICROARRAY RESOLUTION 25
TABLE 13 MICROARRAY GENOME CONTENT 26
TABLE 14 DNA MICROARRAY PLATFORM FEATURES 26
Introduction (Continued) 27
TABLE 15 DNA MICROARRAY PLATFORM COMPARISON FOR
MAJOR MANUFACTURERS 28
Introduction (Continued) 29
STEPS IN THE DNA MICROARRAY EXPERIMENT 30
DNA MICROARRAY APPLICATIONS 30
TABLE 16 DNA MICROARRAY APPLICATIONS 31
TABLE 17 GENETIC ANALYSIS TECHNOLOGIES COMPARISON 32
DNA Microarray Applications 33
FIGURE 3 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT
MAF5 AND MAF1 34
SNP ANALYSIS 34
TABLE 18 SNP MEASUREMENT PLATFORMS 35
EPIGENETIC ANALYSIS 35
Epigenetic Analysis (Continued) 36
FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC
ANALYSIS 37
ChIP-Chip 37
CYTOGENETIC ANALYSIS 38
TABLE 19 COMPARISON OF CHROMOSOMAL CHANGE DETECTION
TECHNOLOGIES 39
MICRO-RNA ANALYSIS 40
TABLE 20 WORKFLOW FOR A MICRO-RNA EXPERIMENT 41
ARRAYS ON BEADS 42
TABLE 21 ARRAYS ON BEADS VERSUS PLANAR MICROARRAYS 42
CATALOG AND CUSTOM DNA MICROARRAYS 43
SUPPLY OF REAGENTS AND SAMPLE PREPARATION FOR
MICROARRAYS 43
TOXICOGENOMICS 44
PROTEIN MICROARRAY TECHNOLOGIES 45
INTRODUCTION 45
FIGURE 5 IMPORTANCE OF PROTEINS 45
PROTEOMICS WORKFLOW 46
FIGURE 6 PROTEIN ANALYSIS APPROACHES CONTRASTED 47
PROTEIN MICROARRAY DESIGN FEATURES 47
TABLE 22 PROTEIN MICROARRAY PLATFORMS 47
Protein Microarray Design Features (Continued) 48
PROTEIN MICROARRAY APPLICATIONS AS RESEARCH
TOOLS 49
TABLE 23 PROTEIN MICROARRAYS AS RESEARCH TOOLS 49
PROTEIN MICROARRAY TYPES 50
TABLE 24 PROTEIN MICROARRAY PRODUCT TYPES 50
TABLE 24 (CONTINUED) 51
Protein Microarray Types (Continued) 52
PROTEIN MICROARRAY TECHNOLOGY CHALLENGES 53
TABLE 25 PROTEIN MICROARRAY TECHNICAL CHALLENGES 53
Protein Microarray Technology … (Continued) 54
EMERGING MICROARRAY TECHNOLOGIES 55
TABLE 26 EMERGING MICROARRAY TECHNOLOGIES 56
GLYCOMICS MICROARRAYS 56
TISSUE MICROARRAYS 57
Tissue Microarrays (Continued) 58
CHAPTER FIVE: LAB-ON-A-CHIP TECHNOLOGIES 59
INTRODUCTION 59
TABLE 27 LOAC PRODUCT LIFE CYCLE STAGE 59
TABLE 28 LOAC SUBSTRATE TECHNOLOGIES 60
LOAC TYPES 61
TABLE 29 LOAC TYPES 61
IN VITRO PROTEOMICS 61
ELECTROPHORESIS ON A CHIP 62
STRUCTURAL PROTEOMICS 62
PCR ON A CHIP 63
IMMUNOASSAYS ON A CHIP 64
MS ON CHIP 65
SEQUENCING ON CHIP 66
TABLE 30 WORKFLOW COMPARISON OF SELECTED NEXTGENERATION
DNA SEQUENCING PLATFORMS 66
TABLE 31 BIOCHIP CONTENT IN NEXT-GENERATION
SEQUENCING MACHINES 67
Sequencing On Chip (Continued) 68
LOAC APPLICATIONS 69
TABLE 32 LOAC MARKET SEGMENTS 69
TABLE 33 MICROFLUIDIC SYSTEMS ADVANTAGES FOR
BIOCHEMICAL ANALYSIS 70
LOAC KEY TECHNOLOGY TRENDS 71
TABLE 34 LOAC KEY TECHNOLOGY TRENDS 71
LOAC KEY TECHNOLOGY TRENDS (CONTINUED) 72
TABLE 35 LOAC TECHNOLOGY PLATFORMS 73
LOAC TECHNOLOGY CHALLENGES 74
TABLE 36 LOAC TECHNOLOGY CHALLENGES 74
LOAC TECHNOLOGY CHALLENGES (CONTINUED) 75
CHAPTER SIX: BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND
DEVELOPMENT 76
BIOCHIP MARKET SEGMENTATION 76
TABLE 37 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS 76
DRUG DISCOVERY AND DEVELOPMENT 77
DRUG INDUSTRY CHALLENGES 78
OVERVIEW OF THE DRUG DISCOVERY AND
DEVELOPMENT PROCESS 78
FIGURE 7 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE 79
TABLE 38 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND
DEVELOPMENT 80
DRUG TARGET IDENTIFICATION 81
DRUG DISCOVERY 82
Structural Biology 82
Lead Generation 82
Lead Generation (Continued) 83
Lead Generation (Continued) 84
Lead Optimization 85
Process R&D 86
Preclinical and Clinical Trials 86
NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT
PROCESS 87
TABLE 39 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT 87
Needs in the Drug Discovery and … (Continued) 88
Needs in the Drug Discovery and … (Continued) 89
FIGURE 8 VALIDATION GAP FOR FUTURE DRUG TARGETS 90
CHAPTER SEVEN: BIOCHIPS DIAGNOSTICS APPLICATIONS 91
INTRODUCTION 91
TABLE 40 DIAGNOSTICS PARADIGM SHIFT 91
HOW DIAGNOSTICS ARE DIFFERENT THAN RESEARCH TOOLS 92
TABLE 41 REQUIREMENTS FOR AN EPIGENETICS BISULFITE
DIAGNOSTIC ASSAY 92
HOW BIOLOGICAL CONTENT DRIVES DIAGNOSTICS’ GROWTH 93
TABLE 42 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS 94
FACTORS IN CLINICAL ACCEPTANCE OF BIOMARKER-BASED
TESTS 95
TABLE 43 RATE OF ADOPTION OF DNA MICROARRAY
DIAGNOSTICS TESTS 96
MOLECULAR DIAGNOSTICS 97
INTRODUCTION 97
MARKET CHALLENGES FOR DNA-BASED MDX
PLATFORMS 98
TABLE 44 COMPARISON OF DNA-BASED MDX PLATFORMS 99
TABLE 45 FACTORS AFFECTING PENETRATION OF NEXTGENERATION
FORMATS INTO THE MDX MARKET 100
Market Challenges for DNA-based MDx Platforms
(Continued) 101
DIAGNOSTICS MARKET SEGMENTS 102
TEST SENSITIVITY AND SPECIFICITY 103
FIGURE 9 SENSITIVITY AND SPECIFICITY 104
REGULATORY STATUS 105
CANCER APPLICATIONS OF BIOCHIPS 106
CANCER OVERVIEW 106
TABLE 46 ESTIMATED US INCIDENCE FOR SELECTED CANCERS,
2010 106
BLADDER CANCER 107
TABLE 47 STATUS OF ADVANCED BLADDER CANCER
DIAGNOSTICS 107
Bladder Cancer (Continued) 108
BREAST CANCER 109
Breast Cancer Screening 109
Prognosis and Pharmacogenetics Tests 110
TABLE 48 ESTIMATED NUMBER OF ANNUAL BREAST CANCER
TREATMENT DECISIONS IN THE US BY CANCER
CLASSIFICATION 110
Breast Cancer MDx Platforms 111
TABLE 49 BREAST CANCER MDX TECHNOLOGY PLATFORMS 111
TABLE 50 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS 112
TABLE 50 (CONTINUED) 113
Breast Cancer MDx Platforms (Continued) 114
Breast Cancer MDx Platforms (Continued) 115
Breast Cancer MDx Platforms (Continued) 116
BRAIN CANCER 117
TABLE 51 STATUS OF ADVANCED BRAIN CANCER DIAGNOSTICS 118
CERVICAL CANCER 118
Cervical Cancer (Continued) 119
TABLE 52 STATUS OF ADVANCED HPV DIAGNOSTICS 120
Cervical Cancer (Continued) 121
COLORECTAL CANCER 122
Conventional Colorectal Cancer Screening Tests 123
TABLE 53 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR
COLORECTAL CANCER 123
Molecular Colorectal Cancer Diagnostics Tests 124
TABLE 54 STATUS OF ADVANCED COLORECTAL CANCER
DIAGNOSTICS 125
Molecular Colorectal … (Continued) 126
Molecular Colorectal … (Continued) 127
CUP 128
CUP (Continued) 129
TABLE 55 STATUS OF ADVANCED CUP DIAGNOSTICS 130
GASTRIC CANCER 131
TABLE 56 STATUS OF GASTRIC/STOMACH CANCER NEXTGENERATION
DX TESTS 132
KIDNEY CANCER 133
TABLE 57 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS 133
LEUKEMIA 134
TABLE 58 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS 134
TABLE 58 (CONTINUED) 135
Leukemia (Continued) 136
LIVER CANCER 137
TABLE 59 STATUS OF LIVER CANCER NEXT-GENERATION DX
TESTS 137
LYMPHOMA CANCERS 138
TABLE 60 STATUS OF ADVANCED LYMPHOMA CANCER
DIAGNOSTICS 139
LUNG CANCER 139
TABLE 61 5-YEAR SURVIVAL RATES FOR NONSMALL CELL LUNG
CANCER (%) 140
TABLE 62 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS 141
TABLE 62 (CONTINUED) 142
Lung Cancer (Continued) 143
Lung Cancer (Continued) 144
MELANOMA 145
TABLE 63 STATUS OF ADVANCED MELANOMA DIAGNOSTICS 145
Melanoma (Continued) 146
OVARIAN CANCER 147
TABLE 64 EARLY SCREENING OVARIAN CANCER TESTS 147
TABLE 65 STATUS OF ADVANCED OVARIAN CANCER
DIAGNOSTICS 148
Ovarian Cancer (Continued) 149
PANCREATIC CANCER 150
TABLE 66 STATUS OF ADVANCED PANCREATIC CANCER
DIAGNOSTICS 150
PROSTATE CANCER 151
TABLE 67 STATUS OF ADVANCED PROSTATE CANCER
DIAGNOSTICS 152
TABLE 67 (CONTINUED) 153
Prostate Cancer (Continued) 154
Prostate Cancer (Continued) 155
THYROID CANCER 156
TABLE 68 STATUS OF ADVANCED THYROID CANCER
DIAGNOSTICS 156
SUMMARY OF ADVANCED CANCER DIAGNOSTICS 157
TABLE 69 NEXT-GENERATION DX TEST SUMMARY BY
INDICATION AND BY TECHNOLOGY 157
BIOCHIPS APPLICATIONS IN WARFARIN SENSITIVITY 158
TABLE 70 IMPORTANCE OF CYP GENES IN DRUG METABOLISM 159
TABLE 71 STATUS OF ADVANCED WARFARIN CYP
PHARMACOGENETIC DIAGNOSTICS 160
TABLE 71 (CONTINUED) 161
BIOCHIPS APPLICATIONS IN WARFARIN … (CONTINUED) 162
BIOCHIPS APPLICATIONS IN INFECTIOUS DISEASE
DIAGNOSTICS 163
TUBERCULOSIS 163
HOSPITAL-ACQUIRED INFECTIONS 164
TABLE 72 STATUS OF MRSA AND C DIFFICILE ADVANCED
DIAGNOSTICS 165
INFLUENZA 166
TABLE 73 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS 166
TABLE 73 (CONTINUED) 167
SEXUALLY TRANSMITTED DISEASES 168
TABLE 74 STATUS OF CHLAMYDIA TRACHOMATIS AND
NEISSERIA GONORRHEA (CT/NG) ADVANCED DIAGNOSTICS 169
OTHER INFECTIOUS DISEASES 169
BIOCHIPS APPLICATIONS IN NEUROLOGICAL DIAGNOSTICS 170
ALZHEIMER’S DISEASE 170
TABLE 75 ALZHEIMER’S DISEASE DIAGNOSTICS APPROACHES 171
TABLE 76 STATUS OF ALZHEIMER’S DISEASE ADVANCED
DIAGNOSTICS TESTS 172
SCHIZOPHRENIA 173
BIOCHIPS APPLICATIONS IN CARDIAC DIAGNOSTICS 174
CONGESTIVE HEART FAILURE 174
TABLE 77 BNP MOLECULAR DIAGNOSTICS TESTS FOR
CONGESTIVE HEART FAILURE 175
OTHER CARDIAC DIAGNOSTICS 176
BIOCHIP APPLICATIONS IN CYSTIC FIBROSIS DIAGNOSTICS 177
TABLE 78 CYSTIC FIBROSIS ADVANCED DIAGNOSTICS TESTS 177
BIOCHIP APPLICATIONS IN CYSTIC … (CONTINUED) 178
BIOCHIPS APPLICATIONS IN PRE- AND POSTNATAL
SCREENING 179
TABLE 79 PRENATAL DIAGNOSTICS TESTS 180
BIOCHIPS APPLICATIONS IN PRE- AND … (CONTINUED) 181
BIOCHIPS APPLICATIONS IN IMMUNE DISEASE DIAGNOSTICS 182
HLA TYPING TESTS 182
TABLE 80 HLA TESTING MARKET 183
AUTOIMMUNE TESTING 184
BIOCHIP APPLICATIONS FOR AG-BIO MARKET 185
TABLE 81 BIOCHIPS IN AG-BIO MARKET 186
BIOCHIP APPLICATIONS FOR AG-BIO … (CONTINUED) 187
CHAPTER EIGHT: BIOCHIPS INDUSTRY 188
ACQUISITIONS 188
TABLE 82 RECENT ACQUISITIONS IN THE BIOCHIPS INDUSTRY,
2008-2011 188
TABLE 82 (CONTINUED) 189
TABLE 82 (CONTINUED) 190
ACQUISITIONS (CONTINUED) 191
ACQUISITIONS (CONTINUED) 192
ACQUISITIONS (CONTINUED) 193
STRATEGIC ALLIANCES 194
TABLE 83 BIOCHIP INDUSTRY STRATEGIC ALLIANCES, 2008-2011 195
TABLE 83 (CONTINUED) 196
STRATEGIC ALLIANCES (CONTINUED) 197
STRATEGIC ALLIANCES (CONTINUED) 198
STRATEGIC ALLIANCES (CONTINUED) 199
STRATEGIC ALLIANCES (CONTINUED) 200
DITIGAL PCR INDUSTRY 201
TABLE 84 DIGITAL PCR INDUSTRY 202
PEPTIDE MICROARRAY INDUSTRY 203
TABLE 85 PEPTIDE MICROARRAY INDUSTRY 204
CHINA BIOCHIP INDUSTRY 205
TABLE 86 CHINA BIOCHIP INDUSTRY 206
LOAC INDUSTRY 207
TABLE 87 LOAC COMPETITOR LANDSCAPE 208
LOAC INDUSTRY (CONTINUED) 209
CHAPTER NINE: BIOCHIPS MARKETS 210
DRIVING FORCES OF BIOCHIPS GROWTH 210
TABLE 88 FORCES DRIVING BIOCHIPS GROWTH 210
GROWTH IN LIFE SCIENCE R&D FUNDING 210
TABLE 89 2009-2010 STIMULUS FUNDING ALLOCATED TO US
SCIENCE SPENDING ($ MILLIONS) 211
LARGE-SCALE GENOMIC, PROTEOMIC, AND BIOCHIP
INITIATIVES 211
DEVELOPMENT OF TARGETED, PERSONALIZED
MEDICINES 212
COST-CONSCIOUS HEALTHCARE SYSTEM 213
RAPIDLY AGING POPULATION IN DEVELOPED REGIONS
OF THE WORLD 213
NEED FOR MORE INNOVATIVE DIAGNOSTIC TESTING
FORMATS 214
ONGOING DISCOVERIES IN GENOMICS AND
PROTEOMICS 214
DISCOVERY OF GENE AND SNP DISEASE ASSOCIATIONS 214
GLOBAL BIOCHIPS MARKET 215
TABLE 90 GLOBAL VALUE OF BIOCHIP PRODUCTS BY
TECHNOLOGY, THROUGH 2016 ($ MILLIONS) 215
TABLE 91 GLOBAL VALUE OF BIOCHIP PRODUCTS BY PRODUCT
TYPE, THROUGH 2016 ($ MILLIONS) 216
TABLE 92 GLOBAL VALUE OF BIOCHIP MARKET BY END USE,
THROUGH 2016 ($ MILLIONS) 217
MICROARRAY MARKETS 218
TABLE 93 GLOBAL VALUE OF MICROARRAYS BY TYPE, THROUGH
2016 ($ MILLIONS) 218
DNA MICROARRAY MARKETS 219
DNA MICROARRAY MARKET BY END-USE INDUSTRY 219
TABLE 94 GLOBAL VALUE OF DNA MICROARRAYS BY END USE,
THROUGH 2016 ($ MILLIONS) 220
NONCLINICAL DNA MICROARRAY MARKET BY
APPLICATION 221
TABLE 95 GLOBAL VALUE OF NONCLINICAL DNA MICROARRAYS
BY APPLICATION, THROUGH 2016 ($ MILLIONS) 221
Nonclinical DNA Microarray … (Continued) 222
Nonclinical DNA Microarray … (Continued) 223
FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002-2010 (NUMBER) 224
DNA MICROARRAY MARKET BY FORMAT 225
TABLE 96 GLOBAL VALUE OF DNA MICROARRAYS BY FORMAT,
THROUGH 2016 ($ MILLIONS) 225
BIOCHIPS DIAGNOSTICS MARKETS 226
BIOCHIPS DIAGNOSTIC MARKET BY INDICATION 226
TABLE 97 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS, BY
INDICATION, THROUGH 2016 ($ MILLIONS) 227
Biochips Diagnostic Market by … (Continued) 228
Biochips Diagnostic Market by … (Continued) 229
Biochips Diagnostic Market by … (Continued) 230
BIOCHIPS DIAGNOSTICS MARKET BY BIOCHIP TYPE 231
TABLE 98 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY TYPE,
THROUGH 2016 ($ MILLIONS) 232
TABLE 99 SEQUENCING IN DIAGNOSTICS 233
BIOCHIPS DIAGNOSTICS MARKET BY ANALYSIS
PERFORMED 234
TABLE 100 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY
ANALYSIS PERFORMED, THROUGH 2016 ($ MILLIONS) 235
BIOCHIPS DIAGNOSTICS MARKET BY FUNCTION 236
TABLE 101 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY
FUNCTION, THROUGH 2016 ($ MILLIONS) 236
CANCER BIOCHIPS MARKETS 237
CANCER DIAGNOSTICS BIOCHIPS MARKET BY
INDICATION 237
TABLE 102 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS,
BY INDICATION, THROUGH 2016 ($ MILLIONS) 238
Cancer Diagnostics Biochips … (Continued) 239
CANCER DIAGNOSTICS BIOCHIPS MARKET BY BIOCHIP
TYPE 240
TABLE 103 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS
BY TECHNOLOGY, THROUGH 2016 ($ MILLIONS) 240
TABLE 104 ADOPTION RATE FOR DNA MICROARRAYS IN
DIAGNOSTICS 241
CANCER BIOCHIPS MARKET BY ANALYSIS PERFORMED 242
TABLE 105 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS,
BY ANALYSIS PERFORMED, THROUGH 2016 ($ MILLIONS) 242
Cancer Biochips Market By Analysis … (Continued) 243
CANCER DIAGNOSTICS BIOCHIPS MARKET BY FUNCTION 244
TABLE 106 GLOBAL VALUE OF CANCER DIAGNOSTICS BIOCHIPS,
BY FUNCTION, THROUGH 2016 ($ MILLIONS) 244
PROTEIN MICROARRAYS MARKETS 245
TABLE 107 COMPETITIVE PLATFORMS BY MULTIPLEXING
DENSITY 245
PROTEIN MICROARRAYS MARKET BY TECHNOLOGY 246
TABLE 108 GLOBAL VALUE OF PROTEIN MICROARRAYS BY
TECHNOLOGY, THROUGH 2016 ($ MILLIONS) 246
Protein Microarrays Market by Technology (Continued) 247
PROTEIN MICROARRAYS MARKET BY PRODUCT FORMAT 248
TABLE 109 GLOBAL VALUE OF PROTEIN MICROARRAYS BY
PRODUCT FORMAT THROUGH 2016 ($ MILLIONS) 248
TABLE 110 COATED MICROARRAY SLIDE MARKET PRINCIPAL
COMPETITORS 249
PROTEIN MICROARRAYS MARKET BY END-USE
INDUSTRY 250
TABLE 111 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END
USE, THROUGH 2016 ($ MILLIONS) 250
EMERGING MICROARRAYS MARKETS 251
EMERGING MICROARRAYS MARKET BY TECHNOLOGY 251
TABLE 112 GLOBAL VALUE OF EMERGING MICROARRAYS, BY
TECHNOLOGY, THROUGH 2016 ($ MILLIONS) 251
EMERGING MICROARRAYS MARKETS BY END-USE
INDUSTRY 252
TABLE 113 GLOBAL VALUE OF EMERGING MICROARRAYS, BY END
USE, THROUGH 2016 ($ MILLIONS) 253
LAB-ON-A-CHIP MARKETS 253
LAB-ON-A-CHIP MARKET BY END-USE INDUSTRY 253
TABLE 114 GLOBAL VALUE OF LAB-ON-A-CHIP DEVICES, BY END
USE, THROUGH 2016 ($ MILLIONS) 254
Lab-On-A-Chip Market by End-Use Industry (Continued) 255
Lab-On-A-Chip Market by End-Use Industry (Continued) 256
Lab-On-A-Chip Market by End-Use Industry (Continued) 257
LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET
BY APPLICATION 258
TABLE 115 GLOBAL VALUE OF LAB-ON-A-CHIP DRUG DISCOVERY
AND DEVELOPMENT MARKET BY APPLICATION, THROUGH
2016 ($ MILLIONS) 258
LOAC Drug Discovery and …(Continued) 259
LOAC Drug Discovery and …(Continued) 260
BIOCHIPS GEOGRAPHICAL MARKETS 261
GLOBAL VALUE OF BIOCHIPS PRODUCTS BY REGION 261
TABLE 116 GLOBAL VALUE OF BIOCHIP PRODUCTS BY REGION,
THROUGH 2016 ($ MILLIONS) 261
DNA MICROARRAY MARKET BY REGION 262
TABLE 117 GLOBAL VALUE OF DNA MICROARRAYS, BY REGION,
THROUGH 2016 ($ MILLIONS) 263
PROTEIN AND EMERGING MICROARRAYS MARKET BY
REGION 264
TABLE 118 GLOBAL VALUE OF PROTEIN AND EMERGING
MICROARRAYS, BY REGION, THROUGH 2016 ($ MILLIONS) 264
LAB-ON-A-CHIP REGIONAL MARKETS 265
TABLE 119 GLOBAL VALUE OF LOAC, BY REGION, THROUGH 2011
($ MILLIONS) 265
CHAPTER TEN: BIOCHIPS PATENTS 266
MICROARRAY PATENTS 266
TABLE 120 ISSUED DNA MICROARRAY PATENTS BY REGION, 2001–
2010 266
TABLE 121 ISSUED PROTEIN MICROARRAY PATENTS BY REGION,
2001–2010 267
TABLE 122 NUMBER OF PATENTS (APPLIED AND ISSUED) FOR
SELECTED MICROARRAY COMPANIES 268
TABLE 123 PATENTS, ISSUED OR APPLIED, FOR SELECTED
MICROARRAY COMPANIES 269
LAB-ON-A-CHIP PATENTS 269
TABLE 124 ISSUED LOAC PATENTS BY REGION, 2001–2010 269
TABLE 125 NUMBER OF PATENTS (APPLIED AND ISSUED) FOR
SELECTED LAB-ON-A-CHIP COMPANIES 270
TABLE 126 PATENTS, ISSUED OR APPLIED, FOR SELECTED LABON-
A-CHIP COMPANIES, BY GEOGRAPHICAL REGION 271
NEXT-GENERATION DNA SEQUENCING PATENTS 272
TABLE 127 NEXT-GENERATION SEQUENCING PATENTS, BY
REGION, 2001–2010 272
TABLE 128 NUMBER OF SEQUENCING-RELATED PATENTS
(APPLIED AND ISSUED) FOR SELECTED COMPANIES 273
NEXT-GENERATION DNA SEQUENCING … (CONTINUED) 274
CHAPTER ELEVEN: COMPANY PROFILES 275
20/20 GENE SYSTEMS, INC 275
ABBOTT LABORATORIES 276
ABTECH SCIENTIFIC, INC 277
ADVANCED LIQUID LOGIC 278
AFFYMETRIX, INC 278
AFFYMETRIX, INC (CONTINUED) 279
TABLE 129 AFFYMETRIX GENECHIP DIAGNOSTIC STATUS 280
AGENDIA BV 281
TABLE 130 AGENDIA MICROARRAY-BASED DIAGNOSTICS
PIPELINE 282
AGENDIA BV (CONTINUED) 283
AGILENT TECHNOLOGIES, INC 284
AKONNI BIOSYSTEMS 284
TABLE 131 AKONNI BIOCHIP GRANTS 285
ALERE TECHNOLOGIES GMBH 286
ALLEGRO DIAGNOSTICS INC 287
ALMAC GROUP, LTD 288
ANAGNOSTICS GMBH 289
ARRAYIT CORPORATION 289
ARRAY-ON GMBH 290
ASSURERX 290
AUSHON BIOSYSTEMS, INC 291
AUTOGENOMICS, INC 291
AVIANA MOLECULAR TECHNOLOGIES 292
AXELA BIOSENSORS 293
AYANDA BIOSYSTEMS SA 294
BECKMAN COULTER, INC 294
BECTON, DICKINSON AND CO 295
BIOCARTIS SA 296
BIOCEPT 296
BIONANOMATRIX, INC 297
BIOSCORA 298
BLUEGNOME, LIMITED 298
BODITECH MED, INC 299
BOEHRINGER INGELHEIM MICROPARTS GMBH 300
CALIPER LIFE SCIENCES 300
CAPITALBIO CORPORATION 301
CARIS MPI 302
CARIS LIFE SCIENCES 303
CELLIX, LTD 303
CEPHEID 304
CHIPDX, LLC 305
CLAROS DIAGNOSTICS, INC 306
COMBIMATRIX CORPORATION 307
TABLE 132 COMBIMATRIX DNA MICROARRAY PLATFORMS 307
CUSTOMARRAY, INC 308
CYTOSCALE DIAGNOSTICS, LLC 308
DECODE GENETICS 309
DIAGENIC ASA 309
TABLE 133 DIAGENIC PATENT PORTFOLIO 310
DIAGNOSTICS FOR ALL 311
DIAGNOSWISS SA 311
DIGITAL GENOMICS 312
DNAMICROARRAY, INC 313
DR CHIP BIOTECH, INC 313
DYCONEX AG 314
ELIM BIOPHARMACEUTICALS, INC 314
EXACT SCIENCES 314
EXACT SCIENCES (CONTINUED) 315
TABLE 134 EXACT SCIENCES STOOL-BASED COLORECTAL
CANCER TEST VERSIONS 316
EXONHIT THERAPEUTICS SA 316
TABLE 135 EXONHIT’S SPLICE-ARRAY DIAGNOSTICS PIPELINE 317
FALCON GENOMICS 318
FEBIT BIOTECH GMBH 319
FLUIDIGM CORPORATION 319
FULL MOON BIOSYSTEMS 320
GE HEALTHCARE LIFESCIENCES 320
GENALYTE 321
GENERA BIOSYSTEMS 321
GENETIC TECHNOLOGIES, LTD 322
GENEWAVE SAS 322
GENMARK DIAGNOSTICS 323
GENOMICA, SAU 324
GENPROBE, INC 325
GENTEL BIOSCIENCES, INC 326
GOOD START GENETICS, INC 327
GWC TECHNOLOGIES 328
HIGH THROUGHPUT GENOMICS, INC 328
HOLOGIC, INC 329
ILLUMINA, INC 329
ILLUMINA, INC (CONTINUED) 330
INOSTICS GMBH 331
INTAVIS BIOANALYTICAL INSTRUMENTS AG 331
IRIS BIOTECHNOLOGIES 332
IRIS INTERNATIONAL, INC 333
JOHNSON & JOHNSON 333
JPT PEPTIDE TECHNOLOGIES GMBH 334
KINEXUS BIOINFORMATICS CORPORATION 335
KONINKLIJKE PHILIPS ELECTRONICS NV 336
LAB21, LTD 336
LC SCIENCES 337
LIFE TECHNOLOGIES, INC 338
LINEAGEN, INC 339
LIONIX BV 340
LUMINEX 340
MAGARRAY, INC 341
MAINE MANUFACTURING 341
MAVEN BIOTECHNOLOGIES 342
MDXHEALTH SA 342
TABLE 136 MDXHEALTH DIAGNOSTICS FOCUS 343
METAMARK GENETICS, INC 344
MICRONICS, INC 344
MINGYUAN MEDICARE DEVELOPMENT COMPANY, LTD 345
MIRA DX 345
MYCROARRAYCOM 346
NANOIVD 346
NANOSPHERE 347
NANOSTRING TECHNOLOGIES 348
NATURALNANO, INC 348
NUVERA BIOSCIENCES 349
ON-Q-ITY 349
OXFORD GENE TECHNOLOGY 350
PAMGENE INTERNATIONAL BV 350
PATHWORK DIAGNOSTICS 351
PATHOGENICA 351
PEPPERPRINT GMBH 352
PEPSCAN PRESTO BV 353
PERKINELMER 353
PERKINELMER (CONTINUED) 354
PHALANX BIOTECH GROUP 355
PLEXERA, LLC 355
PREDICTIVE BIOSCIENCES 356
PROTAGEN AG BIOTECHNOLOGIE 356
PROTAGEN AG BIOTECHNOLOGIE (CONTINUED) 357
PROTEIN BIOTECHNOLOGIES, INC 358
PROTNETEOMIX SAS 358
QIAGEN 359
QUANTALIFE 359
QUANTRX BIOMEDICAL CORPORATION 360
QUANTERIX CORPORATION 360
QUEST DIAGNOSTICS 361
RAINDANCE TECHNOLOGIES, INC 362
RANDOX LABORATORIES, LTD 363
TABLE 137 RANDOX BIOCHIPS ASSAYS PORTFOLIO 364
RAYBIOTECH, INC 365
RHEONIX 365
RIDGE DIAGNOSTICS, INC 365
ROCHE HOLDING AG 366
SCANDINAVIAN MICRO BIODEVICES APS 367
SEEGENE, INC 367
TABLE 138 SEEGENE BIOCHIPS COLLABORATIONS 368
SHANGHAI BIOCHIP CO, LTD 369
SHANGHAI BIODOOR GENE TECHNOLOGY 369
SHANGHAI HUAGUAN BIOCHIP CO, LTD 369
SIALIX, INC 370
SIEMENS AG 370
SIGNAL GENETICS, LLC 371
SIGNATURE DIAGNOSTICS AG 372
SIRS-LABS GMBH 372
SKYLINE DIAGNOSTICS BV 373
SQI DIAGNOSTICS, INC 373
SOMALOGIC, INC 374
TIANJIN BIOCHIP CORPORATION 374
VEREDUS LABORATORIES PTE, LTD 375
WAFERGEN BIOSYSTEMS, INC 375
XAGENIC 376